Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
about
HDAC inhibitors and immunotherapy; a double edged sword?Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencingDendritic cell-based vaccine efficacy: aiming for hot spotsImpact of sepsis on CD4 T cell immunityIdentification of immunogenic LY6K long peptide encompassing both CD4(+) and CD8(+) T-cell epitopes and eliciting CD4(+) T-cell immunity in patients with malignant diseaseConcurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: It takes three to tango.Alterations in antigen-specific naive CD4 T cell precursors after sepsis impairs their responsiveness to pathogen challenge.Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer.Clinical and Experimental Sepsis Impairs CD8 T-Cell-Mediated Immunity.Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions.Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Identification of Melanoma-reactive CD4+ T-Cell Subsets From Human Melanoma Draining Lymph Nodes.T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelIL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age.IL-1βR-dependent priming of antitumor CD4(+) T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria.The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome.T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.Effects of exogenous IL-37 on the biological characteristics of human lung adenocarcinoma A549 cells and the chemotaxis of regulatory T cells.Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.Therapeutic cancer vaccines.Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response.
P2860
Q26853102-7C7ECBF3-341F-48ED-BB9A-9F018095E97DQ27334215-C2F545B2-97CF-49EF-A23D-810B64804954Q28082680-1523A322-7A2E-40F2-87B1-1D01F8E29598Q34341378-00CBDD0E-9B0F-4E32-A7F0-00F097659D1CQ34372937-09FB97E3-F291-40D9-8E3F-0FB9F4677121Q34438014-87E55136-4D65-483C-B336-57A8C391960FQ35546243-19A95FA8-748F-4976-A2E7-7CD6582294B2Q35569528-1AC63444-89C1-4895-B70D-6566D03868F5Q36060333-4E3C9349-6A52-4AA4-9F74-D579ABE47423Q36198732-8F45F0C5-96DB-445B-B18D-CEB832709A5BQ37015682-FF6541BA-6D8A-464B-B05F-7527D88D84E1Q37399278-A7614ECE-011C-4353-8650-8AC8E81A8A5DQ37414561-507A3E35-895B-4BA6-B103-C6817B879D5EQ37616492-38413E81-F7BD-4A5B-A18F-FA387F7598BCQ37649004-CA34265C-0961-47E7-8648-9BBBC7046EE2Q38335303-96431067-61F6-4278-B86F-9876E33649FDQ38733598-1F6294B3-2E67-4403-BC7D-E567FE1BBF3EQ38769021-6967C703-EC28-49FE-AD01-1B827697A8C3Q38814049-D824B4D8-AF6E-49AD-B7B0-EC2C834B7AD4Q38996151-B4F0E65B-4680-47D8-A1F5-B214B593E00DQ39249589-2B8A0363-5E74-453C-B66E-A570A7752952Q39617919-92746BA1-40D7-4EC2-89B4-BAAD25D03DB6Q40449413-C258FF14-191F-4B3A-9674-319AC5E94A93Q41351026-DB2AFEE6-741E-4A95-8896-D5529CCD8E29Q42333881-BE3BD16C-7874-4CBD-A785-07625BFB863DQ42371124-C73B7856-F6D5-4740-A8EA-A3FA9DF42429Q42695310-A0A799E7-0309-4095-95B4-9D26FF259333Q47253631-9E87A7E8-0FCD-4F0A-963C-AFD933215DA5Q47809269-A56AA4D6-4D98-4E6A-8A23-D7B5535F689BQ47950137-A57C8188-E66A-463D-9581-BE024CBEB232Q48185876-8ADAB0D7-870F-47A3-AA0F-A0A305C769B4Q50957786-D8DF470A-1180-49B3-A71A-8A9DFCFD59AFQ50988785-5DCD76BB-4582-4E3F-8E21-F7C1B97957E1Q52775663-4BF36E6F-0E69-4AE3-BE04-3775EACE490CQ55262517-EDDC36B8-567D-4D48-B08E-6C9E2B3875A6
P2860
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@ast
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@en
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@nl
type
label
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@ast
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@en
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@nl
prefLabel
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@ast
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@en
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@nl
P2093
P2860
P356
P1476
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
@en
P2093
Bernard A Fox
Paul A Antony
Sarah E Church
P2860
P356
10.1002/EJI.201343718
P407
P577
2013-11-21T00:00:00Z